Matthew Ross, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 7
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · Genesis Healthcare Partners PC
Looking this up.
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
7 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Matthew Ross’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$34,372
Medicare paid this office $34,372 for 276 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 146 | $12,675 | $68 |
| Return visit (30+ min) | 69 | $8,594 | $102 |
| New patient visit (30+ min) | 52 | $4,169 | $80 |
| Long return visit (40+ min) | 18 | $2,788 | $147 |
| New patient visit (15+ min) | 47 | $2,323 | $49 |
See all 7 services
| Short return visit (20+ min) | 146 | $12,675 | $68 |
| Return visit (30+ min) | 69 | $8,594 | $102 |
| New patient visit (30+ min) | 52 | $4,169 | $80 |
| Long return visit (40+ min) | 18 | $2,788 | $147 |
| New patient visit (15+ min) | 47 | $2,323 | $49 |
| New patient visit (45+ min) | 15 | $1,880 | $125 |
| Short return visit | 23 | $950 | $41 |
Who their Medicare patients are
276 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 8% · Women 73% · Also on Medicaid 19% · Health risk score 1.07. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 34% · Coronary heart disease 25% · Depression 18% · Chronic kidney disease 16% · Cancer 16% · Atrial fibrillation 14% · Heart failure 9% · COPD 8% · Stroke 8% · Dementia 4%.
The office billed $218,935, Medicare allowed $46,641 and paid $34,372; for 447 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 276 | 447 | 74 | 1.07 | $218,935 | $34,372 |
| 2023 | 230 | 321 | 74 | 0.99 | $142,540 | $22,430 |
| 2022 | 26 | 26 | 73 | 1.11 | $9,041 | $2,005 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Short return visit (20+ min) | 130 | $10,483 | $69 |
| Return visit (30+ min) | 39 | $4,381 | $95 |
| Short return visit | 45 | $2,357 | $46 |
| New patient visit (45+ min) | 14 | $1,739 | $124 |
| New patient visit (30+ min) | 19 | $1,583 | $83 |
| New patient visit (15+ min) | 27 | $1,500 | $56 |
2022: 1 service
| Short return visit (20+ min) | 18 | $1,332 | $74 |
Drugs they prescribed that Part D paid
$326,637
Pharmacies billed $326,637 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
644 generic and 175 brand-name prescriptions · $326,637 in drug cost · 28 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zenpep | 12 | $84,192 | $7,016 |
| Creon | 20 | $79,132 | $3,957 |
| Linzess | 35 | $42,922 | $1,226 |
| Mesalamine | 11 | $11,848 | $1,077 |
| Dexlansoprazole Dr | 17 | $5,788 | $340 |
See all 21 drugs
| Zenpep | 12 | $84,192 | $7,016 |
| Creon | 20 | $79,132 | $3,957 |
| Linzess | 35 | $42,922 | $1,226 |
| Mesalamine | 11 | $11,848 | $1,077 |
| Dexlansoprazole Dr | 17 | $5,788 | $340 |
| Sutab | 12 | $1,929 | $161 |
| Cholestyramine Light | 19 | $1,879 | $99 |
| Plenvu | 12 | $1,732 | $144 |
| Sod Sulf-Potass Sulf-Mag Sulf | 23 | $1,489 | $65 |
| Pantoprazole | 93 | $1,390 | $15 |
| Lansoprazole | 27 | $1,390 | $51 |
| Omeprazole | 70 | $865 | $12 |
| Famotidine | 95 | $832 | $9 |
| Gavilyte-G | 48 | $741 | $15 |
| Esomeprazole Magnesium | 16 | $469 | $29 |
| Rabeprazole | 16 | $346 | $22 |
| Hydrocortisone | 19 | $335 | $18 |
| Diphenoxylate-Atropine | 15 | $327 | $22 |
| Peg 3350-Electrolyte | 16 | $319 | $20 |
| Dicyclomine | 23 | $253 | $11 |
| Peg-3350 and Electrolytes | 21 | $200 | $10 |
Year by year
| 2024 | 819 | 314 | None | 21% | $326,637 |
| 2023 | 976 | 339 | 0% (0) | 26% | $497,936 |
| 2022 | 576 | 193 | 0% (0) | None | $178,240 |
| 2021 | 147 | 77 | 0% (0) | 18% | $20,148 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Zenpep | 17 | $105,034 | $6,178 |
| Creon | 34 | $94,781 | $2,788 |
| Xifaxan | 17 | $44,509 | $2,618 |
| Linzess | 34 | $32,620 | $959 |
| Dexlansoprazole Dr | 34 | $17,486 | $514 |
| Mesalamine | 18 | $13,749 | $764 |
| Sod Sulf-Potass Sulf-Mag Sulf | 65 | $4,847 | $75 |
| Pantoprazole | 123 | $3,161 | $26 |
| Esomeprazole Magnesium | 21 | $2,191 | $104 |
| Famotidine | 110 | $1,891 | $17 |
| Cholestyramine Light | 14 | $1,838 | $131 |
| Cholestyramine | 14 | $1,504 | $107 |
| Omeprazole | 67 | $1,157 | $17 |
| Lansoprazole | 28 | $1,117 | $40 |
| Sucralfate | 21 | $977 | $47 |
| Hydrocortisone | 19 | $803 | $42 |
| Gavilyte-G | 34 | $624 | $18 |
| Propranolol | 22 | $256 | $12 |
| Dicyclomine | 18 | $252 | $14 |
| Diphenoxylate-Atropine | 11 | $157 | $14 |
| Amitriptyline | 12 | $74 | $6 |
2022: 12 drugs
| Creon | 15 | $35,837 | $2,389 |
| Linzess | 25 | $20,889 | $836 |
| Trulance | 15 | $8,274 | $552 |
| Dexilant | 11 | $7,716 | $701 |
| Motegrity | 12 | $6,001 | $500 |
| Sucralfate | 49 | $2,815 | $57 |
| Pantoprazole | 87 | $1,680 | $19 |
| Famotidine | 51 | $1,282 | $25 |
| Omeprazole | 42 | $742 | $18 |
| Dicyclomine | 27 | $506 | $19 |
| Peg-3350 and Electrolytes | 14 | $206 | $15 |
| Gavilyte-G | 13 | $195 | $15 |
2021: 4 drugs
| Sucralfate | 18 | $577 | $32 |
| Pantoprazole | 23 | $484 | $21 |
| Omeprazole | 13 | $150 | $12 |
| Famotidine | 12 | $117 | $10 |
Money from drug and device companies
$2,094 in 2025
| 2025 | 16 | 93 | None | $2,094 |
| 2024 | 15 | 107 | None | $1,882 |
| 2023 | 14 | 91 | None | $1,702 |
| 2022 | 8 | 67 | None | $1,006 |
| 2021 | 7 | 26 | None | $619 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $588 | 32 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $328 | 15 payments
|
| Janssen Biotech | Tremfya | $301 | 14 payments
|
| Gilead Sciences | Livdelzi | $224 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $151 | 6 payments
|
| Celltrion USA | Vegzelma | $98 | 5 payments
|
See all 93 published payments
| Janssen Biotech | Meals · 2025-12-29 | Tremfya | $28 |
| Janssen Biotech | Meals · 2025-12-16 | Tremfya | $25 |
| Celltrion USA | Meals · 2025-11-18 | Vegzelma | $20 |
| Ardelyx | Meals · 2025-11-06 | Ibsrela | $17 |
| Abbvie | Meals · 2025-10-30 | Creon | $25 |
| Recordati Rare Diseases Inc. | Meals · 2025-10-28 | Panhematin | $29 |
| Abbvie | Meals · 2025-10-22 | Creon | $9 |
| Abbvie | Meals · 2025-10-21 | Skyrizi | $24 |
| Abbvie | Meals · 2025-10-15 | Viberzi | $26 |
| Janssen Biotech | Meals · 2025-10-01 | Tremfya | $8 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-22 | Xifaxan | $11 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-22 | Xifaxan | $16 |
| Abbvie | Meals · 2025-09-16 | Rinvoq | $28 |
| Abbvie | Meals · 2025-09-10 | Linzess | $26 |
| Abbvie | Meals · 2025-08-28 | Viberzi | $25 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-08-25 | Xifaxan | $13 |
| Gilead Sciences | Meals · 2025-08-14 | None | $7 |
| Abbvie | Meals · 2025-08-13 | Rinvoq | $25 |
| Abbvie | Meals · 2025-08-08 | Linzess | $20 |
| Abbvie | Meals · 2025-07-31 | Viberzi | $6 |
| Celltrion USA | Meals · 2025-07-31 | Vegzelma | $24 |
| Abbvie | Meals · 2025-07-30 | Rinvoq | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-07-28 | Xifaxan | $22 |
| Abbvie | Meals · 2025-07-17 | Linzess | $14 |
| Janssen Biotech | Meals · 2025-07-15 | Tremfya | $27 |
| Abbvie | Meals · 2025-07-14 | Rinvoq | $24 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-07-09 | Xifaxan | $23 |
| Pfizer | Meals · 2025-06-24 | Xeljanz | $16 |
| Gilead Sciences | Meals · 2025-06-19 | None | $26 |
| Ardelyx | Meals · 2025-06-18 | Ibsrela | $16 |
| Abbvie | Meals · 2025-06-13 | Linzess | $15 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-11 | Xifaxan | $111 |
| Janssen Biotech | Meals · 2025-06-10 | Tremfya | $19 |
| Ardelyx | Meals · 2025-06-09 | Ibsrela | $29 |
| Abbvie | Meals · 2025-06-06 | Linzess | $7 |
| Abbvie | Meals · 2025-06-05 | Linzess | $1 |
| Celltrion USA | Meals · 2025-06-05 | Vegzelma | $16 |
| Braintree Laboratories | Meals · 2025-06-03 | Sutab | $45 |
| Fresenius Kabi USA | Meals · 2025-05-29 | None | $35 |
| Phathom Pharmaceuticals | Meals · 2025-05-28 | Voquezna | $28 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-27 | Xifaxan | $13 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-27 | Xifaxan | $8 |
| Intercept Pharmaceuticals | Meals · 2025-05-15 | Ocaliva | $30 |
| Vivus | Meals · 2025-05-06 | Pancreaze | $24 |
| Abbvie | Meals · 2025-05-06 | Linzess | $12 |
| Abbvie | Meals · 2025-05-05 | Rinvoq | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-01 | Entyvio | $19 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $20 |
| Gilead Sciences | Meals · 2025-04-30 | None | $25 |
| Janssen Biotech | Meals · 2025-04-24 | Tremfya | $34 |
| Abbvie | Meals · 2025-04-22 | Skyrizi | $23 |
| Abbvie | Meals · 2025-04-17 | Linzess | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Entyvio | $27 |
| Abbvie | Meals · 2025-04-08 | Linzess | $11 |
| Celltrion USA | Meals · 2025-04-08 | Vegzelma | $19 |
| Janssen Biotech | Meals · 2025-04-03 | Tremfya | $13 |
| Vivus | Meals · 2025-04-03 | Pancreaze | $25 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-28 | Xifaxan | $12 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-28 | Xifaxan | $12 |
| Abbvie | Meals · 2025-03-27 | Rinvoq | $13 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-26 | Eohilia | $26 |
| Janssen Biotech | Meals · 2025-03-24 | Tremfya | $28 |
| Abbvie | Meals · 2025-03-20 | Viberzi | $27 |
| Abbvie | Meals · 2025-03-15 | Linzess | $7 |
| Abbvie | Meals · 2025-03-12 | Rinvoq | $26 |
| Gilead Sciences | Meals · 2025-03-10 | None | $8 |
| Ardelyx | Meals · 2025-03-10 | Ibsrela | $29 |
| Janssen Biotech | Meals · 2025-03-06 | Tremfya | $10 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-06 | Xifaxan | $15 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-05 | Entyvio | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-28 | Xifaxan | $24 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $26 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $6 |
| Abbvie | Meals · 2025-02-25 | Linzess | $12 |
| Novo Nordisk | Meals · 2025-02-24 | Wegovy | $31 |
| Gilead Sciences | Meals · 2025-02-19 | None | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-13 | Entyvio | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-12 | Xifaxan | $20 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-12 | Xifaxan | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-10 | Eohilia | $34 |
| Abbvie | Meals · 2025-02-06 | Creon | $15 |
| Abbvie | Meals · 2025-02-06 | Rinvoq | $27 |
| Abbvie | Meals · 2025-02-04 | Creon | $25 |
| Braintree Laboratories | Meals · 2025-01-30 | Sutab | $23 |
| Janssen Biotech | Meals · 2025-01-28 | Tremfya | $25 |
| Abbvie | Meals · 2025-01-27 | Linzess | $7 |
| Gilead Sciences | Meals · 2025-01-24 | Livdelzi | $131 |
| Abbvie | Meals · 2025-01-23 | Linzess | $14 |
| Celltrion USA | Meals · 2025-01-22 | Vegzelma | $20 |
| Janssen Biotech | Meals · 2025-01-14 | Tremfya | $32 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-01-10 | Xifaxan | $7 |
| Madrigal Pharmaceuticals | Meals · 2025-01-08 | Rezdiffra | $25 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,882
| Abbvie | Linzess | $583 | 34 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $403 | 32 payments
|
| Gilead Sciences | None | $248 | 12 payments
|
| Celltrion USA | Vegzelma | $102 | 4 payments
|
| Pfizer | Xeljanz | $97 | 4 payments
|
| Janssen Biotech | Stelara | $87 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $73 | 4 payments
|
| Braintree Laboratories | Suflave | $54 | 3 payments
|
| Ipsen Biopharmaceuticals | Iqirvo | $49 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $45 | 2 payments
|
| Lilly USA | Omvoh | $41 | 2 payments
|
| Ironwood Pharmaceuticals | Linzess | $37 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $29 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $18 | 1 payment
|
| QOL Medical | Sucraid | $17 | 1 payment
|
2023: $1,702
| Abbvie | Rinvoq | $518 | 34 payments
|
| Gilead Sciences | Vemlidy | $303 | 13 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $181 | 15 payments
|
| Nestle Healthcare Nutrition | Zenpep | $156 | 6 payments
|
| Intercept Pharmaceuticals | Ocaliva | $106 | 4 payments
|
| Aimmune Therapeutics | Vowst | $96 | 3 payments
|
| Ardelyx | Ibsrela | $80 | 3 payments
|
| Novo Nordisk | Wegovy | $62 | 3 payments
|
| Janssen Biotech | Stelara | $47 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $41 | 2 payments
|
| RedHill Biopharma | Talicia | $31 | 2 payments
|
| Celgene | Zeposia | $29 | 1 payment
|
| Merck Sharp & Dohme | None | $28 | 2 payments
|
| Vivus | Pancreaze | $24 | 1 payment
|
2022: $1,006
| Abbvie | Humira | $581 | 37 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $204 | 20 payments
|
| Gilead Sciences | None | $66 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $55 | 3 payments
|
| Ardelyx | Ibsrela | $28 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $25 | 1 payment
|
| Novo Nordisk | Saxenda | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $22 | 1 payment
|
2021: $619
| Biohaven Pharmaceuticals | Nurtec Odt | $156 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $152 | 19 payments
|
| GlaxoSmithKline | Nucala | $125 | 1 payment
|
| Novo Nordisk | Ozempic | $117 | 1 payment
|
| AbbVie | Creon | $40 | 2 payments
|
| RedHill Biopharma | Talicia | $15 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1124601422
- Licence
- CA 95017256
- Group
- Stanford Health Care · Genesis Healthcare Partners PC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2021-05-04
- NPI last updated
- 2026-02-03
- NPI record certified
- 2026-02-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 333 Sunol St Unit 564, San Jose, CA, 95126